

Figure 1




Figure 2

The Enterohepatic Circulation with Key Transporter Proteins Mediating Bile Acid Circulation





Figure 3

Bile Acid Conjugates of HMG-CoA Reductase Inhibitor



HR 780




Figure 4




Figure 5






Figure 6



R₁ = α -OH ; R₂ = α -OH (Cholate)

R₁ = β -OH ; R₂ = H (Ursodeoxycholate)

R₁ = α -OH ; R₂ = H (Chenodeoxycholate)

R₁ = H ; R₂ = α -OH (Deoxycholate)

R₁ = β -OH ; R₂ = α -OH (Ursodecholate)

R₁ = H ; R₂ = H (Lithocholate)

Figure 7




Figure 8




Figure 9: Uptake of (8) (XP10569) or Glycochoolate by IBAT-Transfected CHO Cells




Figure 10: Uptake of (8) (XP10569) or Glycocholate by LBAT-Transfected CHO Cells




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18




Figure 19




Figure 20




Figure 21





Figure 22



Compounds (92) - (103) prepared following methods described in co-pending application "Bile Acid-Derived Compounds for Enhancing Oral Absorption and Systemic Bioavailability of Drugs" assigned to XenoPort, Inc.

Figure 23




Figure 24




Figure 25




Figure 26




Figure 27




Figure 28




Figure 29




Figure 30




Figure 31




Figure 32




Figure 33

